IP Library Granted Patent US 10,166,232
Granted Patent B2
US 10,166,232 · App. 14/879,257 · Granted Jan 1, 2019

Arylamide compounds and compositions and uses thereof

Inventor: Richard W. Scott (Radnor, PA)
Assignee: Innovation Pharmaceuticals Inc.
A61K31/506A61K9/0046A61K9/0048A61K9/0051A61K9/06A61K9/08A61K31/573A61K31/74A61K47/06A61K47/183A61K47/186A61K47/38C07D239/02C07D239/24C07D239/28C07D403/14Y02A50/473
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,166,232
App. No.
14/879,257
Granted
Jan 1, 2019
Kind
B2
Abstract

The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.

Claims (11)

1. A pharmaceutical composition comprising a compound having the formula:

or a pharmaceutically acceptable salt thereof, and water.

2. The composition of claim 1 further comprising Tris-buffered saline.

3. The composition of claim 1 further comprising Farnesol, polyethylene glycol, and Tris-buffered saline.

4. The composition of claim 1 further comprising an additional medicament.

5. The composition of claim 4 wherein the additional medicament is chosen from an antibiotic, an anti-inflammatory agent, an anesthetic agent, an anti-allergic agent, an acetylcholine blocking agent, an adrenergic agonist, a beta-adrenergic blocking agent, an anti-glaucoma agent, and an anti-hypertensive agent.

6. The composition of claim 5 wherein the anti-inflammatory agent is a steroidal agent or a non-steroidal agent.

7. The composition of claim 6 wherein the steroidal agent is chosen from dexamethasone, rimexolone, prednisolone, fluorometholone, and hydrocortisone, and wherein the non-steroidal agent is chosen from a cyclooxygenase type I or type II inhibitor, a PAF antagonist, a PDE IV inhibitor, and an inhibitor of cytokine production.

8. The composition of claim 5 wherein the anti-allergic agent is a corticosteroid.

9. The composition of claim 8 wherein the corticosteroid is chosen from prednisolone, fluorometholone, loteprenol, and dexamethasone.

10. The composition of claim 1 wherein the pharmaceutically acceptable salt is a hydrochloride acid addition salt.

Assignments (3)
CHANGE OF NAME Recorded Nov 2, 2017
From: CELLCEUTIX CORPORATION
To: INNOVATION PHARMACEUTICALS INC.
Reel/Frame 044360/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: SCOTT, RICHARD W.
To: POLMEDIX, INC.
Reel/Frame 038717/0571 →
BANKRUPTCY COURT ORDER/ASSET PURCHASE AGREEMENT Recorded May 25, 2016
From: POLYMEDIX, INC.
To: CELLCEUTIX CORPORATION
Reel/Frame 038810/0112 →
Continuity (4)
Continuation 13661466 · Oct 26, 2012
Continuation 11965194 · Dec 27, 2007
Provisional Application 60882800 · Dec 29, 2006
Related Publication 20160228435A1 · Aug 11, 2016